A study to evaluate the effects of human lymphoblastoid interferon (HLBI) in hepatitis C patients with compensated cirrhosis.
Phase 3
- Conditions
- Chronic hepatitis C with compensated cirrhosis
- Registration Number
- JPRN-jRCT2080220477
- Lead Sponsor
- Dainippon Sumitomo Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
-Compensated cirrhosis patients
-Patients aged 20 to less than 76
etc.
-Patients with chronic liver diseases except chronic hepatitis C with compensated cirrhosis, such as autoimmune hepatitis, alcoholic hepatitis, and drug-induced liver injury.
-Decompensated cirrhosis patients
etc.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy: Sustained viral response rates, etc. Safety
- Secondary Outcome Measures
Name Time Method